<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00237354</url>
  </required_header>
  <id_info>
    <org_study_id>PV-10-BC-04</org_study_id>
    <nct_id>NCT00237354</nct_id>
  </id_info>
  <brief_title>PV-10 Chemoablation of Recurrent Breast Carcinoma</brief_title>
  <official_title>A Phase 1 Safety and Tolerability Study of PV-10 Chemoablation of Recurrent Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Provectus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Provectus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the&#xD;
      treatment of recurrent breast carcinoma. This study will also include a preliminary&#xD;
      assessment of response of injected lesions by histologic assessment upon lesion excision at&#xD;
      1-3 weeks following IL PV-10 administration. Post-excision wound healing will be assessed&#xD;
      clinically at 1 week and 4 weeks following excision of PV-10 injected lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open label, ascending dose study. Subjects with at least one&#xD;
      recurrent, histologically confirmed measurable soft tissue breast carcinoma who are&#xD;
      candidates for lumpectomy (removal of the lesion from the site of recurrence in the breast or&#xD;
      at another site) or mastectomy will receive a single intralesional injection of PV-10 into a&#xD;
      single target lesion to uniformly infiltrate the target lesion and up to a 0.5 cm margin at a&#xD;
      dose of up to 1.0 mL/cc lesion volume. Systemic and locoregional adverse events will be&#xD;
      monitored over the study interval. Subject accrual and PV-10 administration will be stopped&#xD;
      if more than 1 subject has a treatment related Grade 3 non-hematological or Grade 4&#xD;
      hematological toxicity within a period of two weeks after PV-10 administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic and locoregional adverse experience</measure>
    <time_frame>5-7 weeks post dosing (4 weeks post excision)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histopathologic response of PV-10 injected lesions</measure>
    <time_frame>7-21 days post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound healing of PV-10 injected lesions</measure>
    <time_frame>5-7 weeks post dosing (4 weeks post excision)</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PV-10 (rose bengal disodium 10%)</intervention_name>
    <description>PV-10 ablation of study lesion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy confirmed recurrent soft tissue breast carcinoma&#xD;
&#xD;
          -  At least one measurable target lesion at least 0.5 cm and no more than 3 cm in longest&#xD;
             diameter&#xD;
&#xD;
          -  Performance Status: Karnofsky 70-100% or ECOG 0-2&#xD;
&#xD;
          -  Life Expectancy: At least 6 months&#xD;
&#xD;
          -  Hematopoietic:&#xD;
&#xD;
               -  White blood cell count (WBC) at least 3000/mm3&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) at least 1.5 (1,500/mm3)&#xD;
&#xD;
               -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
               -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Coagulopathy: International Normalized Ratio (INR) at least 1.5.&#xD;
&#xD;
          -  Renal Function: Creatinine = 0.05-0.11 mmol/L&#xD;
&#xD;
          -  Hepatic Function:&#xD;
&#xD;
               -  Bilirubin = 3-21 umol/L&#xD;
&#xD;
               -  AST/ALT â‰¤ 3 times the upper limit of normal (ULN)&#xD;
&#xD;
          -  Cardiovascular Function: No major cardiovascular disease&#xD;
&#xD;
          -  Thyroid Function: T3 (serum triiodothyronine), T4 (serum thyroxine) and THS (serum&#xD;
             thyrotropin) within normal limits&#xD;
&#xD;
          -  Immunological Function: Adequate immune system function in the opinion of the&#xD;
             investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiation therapy to study lesions within 4 weeks&#xD;
&#xD;
          -  Chemotherapy or other systemic cancer therapy within 4 weeks (6 weeks for nitrosoureas&#xD;
             or mitomycin)&#xD;
&#xD;
          -  Local treatment (e.g., surgery, cryotherapy, radiofrequency ablation) to the treatment&#xD;
             area within 4 weeks&#xD;
&#xD;
          -  Investigational agents within 4 weeks (or 5 half-lives)&#xD;
&#xD;
          -  Anti-tumor vaccine therapy within 12 weeks&#xD;
&#xD;
          -  Concurrent illness:&#xD;
&#xD;
               -  Severe diabetes or extremity complications due to diabetes&#xD;
&#xD;
               -  Significant concurrent disease or illness, psychiatric disorders, or alcohol or&#xD;
                  chemical dependence that would, in the opinion of the investigator, compromise&#xD;
                  subject safety or compliance or interfere with interpretation of study results&#xD;
&#xD;
               -  Thyroid autoregulatory dysfunction, including thyroid disease (subclinical or&#xD;
                  ongoing), goiter, partial thyroidectomy, prior radioiodine- or surgically-treated&#xD;
                  Graves' hyperthyroidism, or cystic fibrosis&#xD;
&#xD;
          -  Pregnancy or fertile female subjects who are not using effective contraception, or who&#xD;
             are lactating&#xD;
&#xD;
          -  Known or suspected brain metastases or spinal cord compression.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Wachter, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Provectus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Wynne, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Service, Christchurch Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Canterbury BreastCare</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>October 7, 2005</study_first_submitted>
  <study_first_submitted_qc>October 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>October 22, 2008</last_update_submitted>
  <last_update_submitted_qc>October 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Eric Wachter, Ph.D.</name_title>
    <organization>Provectus Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Recurrent soft tissue breast carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

